The challenges behind the promise of reimbursement
This article was originally published in Clinica
From R&D to market approval, funding, clinical and cost-effectiveness assessments, cost-containment in ever tighter national and regional healthcare budgets are part of the minefield that is the medical devices and diagnostics industry. Reimbursement provides certain guarantees in an increasingly competitive and regulated environment. The issue, however, is far from simple. A new study published by Clinica Reports seeks to clarify where the industry stands in the key European and US markets
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.